Table 2.
Distribution of patients’ characteristics according to CD318hi and CD318lo
| Best available alternative therapy | Anthracycline-based induction therapy | |||||
|---|---|---|---|---|---|---|
| Number of patients (%) | Number of patients (%) | |||||
| CD318lo (SFI < 3.2) n = 19 | CD318hi (SFI ≥ 3.2) n = 9 | p value | CD318lo (SFI < 1.17) n = 21 | CD318hi (SFI ≥ 1.17) n = 21 | p value | |
| Sex | ||||||
| Male | 13 (68.5) | 5 (55.5) | 0.51┘ | 9 (43) | 12 (57) | 0.35┘ |
| Female | 6 (31.5) | 4 (44.5) | 12 (57) | 9 (435) | ||
| Median age (years) | 73 (range 26–83) | 78 (range 58–85) | 0.15† | 47 (range 23–73) | 58 (range 21–74) | 0.27† |
| FAB classification | 0.19‡ | 0.15‡ | ||||
| M0 | 2 (10.5) | 3 (37.5) | 1 (5) | 0 (0) | ||
| M1 | 4 (21) | 2 (25) | 3 (14) | 5 (24) | ||
| M2 | 2 (10.5) | 2 (25) | 3 (14) | 7 (33) | ||
| M3 | 0 (0) | 0 (0) | 4 (19) | 1 (4.5) | ||
| M4 | 2 (10.5) | 0 (0) | 7 (33) | 3 (14) | ||
| M5 | 5 (26.5) | 1 (12.5) | 2 (9) | 1 (4.5) | ||
| M6 | 4 (21) | 0 (0) | 1 (5) | 4 (20) | ||
| Unfavorable FAB | 6 (32.5) | 3 (37.5) | 0.77┘ | 2 (9.5) | 4 (19) | 0.37┘ |
| WHO classification | 0.13‡ | 0.68‡ | ||||
| AML with recurrent genetic abnormalities | 9 (48) | 1 (11) | 15 (71) | 12 (57) | ||
| AML with myelodysplasia-related changes | 5 (26) | 3 (33.5) | 1 (5) | 3 (14) | ||
| Therapy-related myeloid neoplasms | 0 (7) | 1 (11) | 1 (5) | 1 (5) | ||
| Myeloid neoplasms with germline predisposition | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| AML, not otherwise specified | 5 (26) | 4 (44.5) | 4 (19) | 5 (24) | ||
| Primary/secondary AML | ||||||
| Primary | 14 (74) | 5 (33) | 0.052┘ | 19 (90.5) | 16 (76) | 0.21┘ |
| Secondary | 3 (26) | 6 (67) | 2 (9.5) | 5 (24) | ||
| Blood count | ||||||
| WBC (G/L) | 137.4 | 32.5 | 0.0006† | 79.9 | 112.7 | 0.25† |
| Hb (g/dl) | 8.6 | 8.8 | 0.69† | 8.2 | 8.2 | 0.98† |
| Plt (G/L) | 66.7 | 66.2 | 0.98† | 51.5 | 75.7 | 0.15† |
| NCCN risk score distribution | 0.03‡ | 0.28‡ | ||||
| Favorable | 7 (37) | 0 (0) | 11 (52.5) | 6 (29) | ||
| Intermediate | 6 (31.5) | 6 (67) | 5 (24) | 7 (33) | ||
| Poor | 4 (21) | 3 (33) | 3 (14) | 7 (33) | ||
| Not classified | 2 (10.5) | 0 (0) | 2 (9.5) | 1 (5) | ||
| Complete response after induction therapyπ | n/a | n/a | n/a | 15 (75) | 12 (57) | 0.23┘ |
FAB, French-American-British; WBC, white blood count; Hb, hemoglobin; Plt, thrombocytes; NCCN, National Comprehensive Cancer Network
πonly patients receiving anthracycline-based induction therapy, response assessment: on day 25–35 after induction (CR, CRi). Statistical analysis with ┘Fisher’s exact test, ‡Pearson-Chi square and †students t test